Physician profile
Timothy D Webb
NPI 1154721645
$7,604.33
in general payments reported to CMS, 2019-2025
38 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $973 · 2021: $596 · 2022: $718 · 2023: $863 · 2024: $1,315 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.21 | 2019-2025 | Vraylar, Qulipta, Viberzi |
| Amgen INC. | $949.25 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $742.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $629.29 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $488.42 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $422.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $328.25 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.01 | 2025 | Caplyta |
| Allergan, INC. | $285.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.70 | 2022-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $249.81 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.33 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.84 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $163.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $141.88 | 2019 |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.